Resources Repository
-
ReviewPublication 2023Adaptive Health Technology Assessment: A Scoping Review of Methods
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, …
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, aiming to support universal health coverage by leveraging HTA evidence from other settings. The scoping review identified and mapped existing aHTA methods, examining their triggers, strengths, and weaknesses. Methods included searching HTA agencies' and networks' websites, and published literature, with findings narratively synthesized. The review found aHTA methods in 20 countries and one HTA network across the Americas, Europe, Africa,…
Technology Assessment | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Global -
ReviewPublication 2023Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and …
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and health technology assessments (HTA). Environmental spillovers, such as CO2 emissions, water and energy consumption, and waste disposal, significantly impact human and planetary health but are often excluded from HTAs. The review's objective is to identify economic evaluations and guidelines incorporating environmental dimensions. Methods included electronic searches of PubMed, Scopus, and EMBASE, as well as official health agencies' guidelines. Documents were…
Technology Assessment | Evidence Synthesis | Cost-Effectiveness Analysis | Environmental Health | Climate/Environment | Health/Medicine | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Technology Assessment | Preferences/Values | Evidence Synthesis | Policy/Regulation | Health/Medicine -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Technology Assessment | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine | Latin America & Caribbean -
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Technology Assessment | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Technology Assessment | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Technology Assessment | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America